Prediction: 1 Value Stock That Will Be Worth More Than Palantir by the End of 2026

Amid growing concerns of an AI stock bubble, Palantir (PLTR) is noted for its rapid market cap growth to $450 billion and strong Q2 revenue increase of 48% driven by its AI platform, yet it carries an extremely high forward P/E of 292. Conversely, UnitedHealth (UNH) is presented as a potential value play, despite current headwinds from rising medical costs and a DOJ investigation into Medicare Advantage. UnitedHealth's management recently raised its 2025 earnings outlook and anticipates improved Optum margins from 2027, with its stock trading at a more modest 21x 2026 earnings, suggesting a potential path to over $400 billion valuation by next year if regulatory clarity and operational improvements materialize.

Analysis

The current market exhibits growing concerns over an AI bubble, with high valuations and circular financing deals echoing the dot-com era. Palantir (PLTR), a significant beneficiary, has seen its market cap surge from $13.4 billion in late 2022 to $450 billion, driven by a 48% year-over-year Q2 revenue climb exceeding $1 billion and a 46% operating margin. However, this growth is accompanied by an "outrageous" forward P/E of 292 and a P/S ratio over 100, significantly above its projected $1.9 billion adjusted net income for 2025.

Despite strong operational performance, including a $10 billion U.S. Army deal and successful AIP adoption, Wall Street analysts largely rate PLTR as "hold" or "sell," with a median price target of $165 per share, implying a market cap of approximately $391 billion. This suggests a potential downside from its current valuation, making Palantir highly susceptible if the AI trend cools, as reflected by its negative per-ticker sentiment of -0.4.

Conversely, UnitedHealth (UNH) is presented as a potential value play, despite facing significant headwinds such as rising medical costs, higher utilization rates, and a Department of Justice investigation into Medicare Advantage billing practices, which could lead to a multibillion-dollar clawback. The company also faces broader regulatory and antitrust scrutiny. However, management recently raised the low end of its 2025 earnings outlook by $0.25 per share and anticipates improved profit margins for its Optum segment starting in 2027.

UNH currently trades at approximately 21 times its 2026 earnings expectations, which is below its five-year average, and carries a positive per-ticker sentiment of 0.5. If regulatory clarity emerges and steady earnings growth resumes, the stock's multiple could expand, potentially leading to a valuation exceeding $400 billion by the end of next year, offering a contrasting investment profile to PLTR's current high valuation.

Key Decisions for Investors

• Investors should critically evaluate growth stocks like Palantir (PLTR) given its extremely high valuation metrics, including a forward P/E of 292, and the broader concerns of an AI market bubble.
• Consider rebalancing portfolios towards value-oriented opportunities such as UnitedHealth (UNH), which, despite current regulatory and cost headwinds, offers a more attractive valuation at 21x 2026 earnings and has positive management guidance for future profitability.
• Monitor regulatory developments for UnitedHealth, particularly the DOJ investigation and potential antitrust actions, as clarity on these issues could significantly impact its stock performance and valuation expansion.
• For PLTR, watch for any signs of slowing AI adoption or shifts in market sentiment towards growth stocks, as its current valuation appears to price in substantial future growth that may be vulnerable to market corrections.